Loading...
NPI 1013663558 · Arlington Heights, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Clarity Testing Services is a clinical medical laboratory provider located in Arlington Heights, Illinois. This profile covers 4 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Clarity Testing Services |
| Address | 1675 S Arlington Heights Rd # Rr |
| City | Arlington Heights |
| State | IL |
| ZIP | 60005 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 23, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.2M |
| Medicaid | $353.5K |
CLARITY TESTING SERVICES is operating primarily as a high-volume COVID-19 diagnostic laboratory: Medicare top codes are U0003, G2023 and U0005 and together account for 85.2% of its total Medicare revenue, indicating the business model is heavily weighted toward SARS‑CoV‑2 nucleic acid testing and associated specimen collection services. The presence of 87811 in Medicare and Medicaid top lists further supports substantial antigen/immunoassay testing activity.
Revenue concentration is extreme on both payers. For Medicare, the precomputed top‑3 codes drive 85.2% of Medicare revenue, and for Medicaid the top‑3 codes drive 84.9% of Medicaid revenue, showing the provider’s income is highly dependent on a narrow set of COVID‑19 testing services rather than a broad laboratory panel. This concentration suggests sensitivity to changes in testing demand or reimbursement for those specific codes.
Scale of operations favors Medicare: lifetime Medicare revenue is $5.2M versus Medicaid revenue of $353.5K, so Medicare is the dominant payer by reported dollars. While both payers show the same service focus, the provider is effectively Medicare‑scale dominant, not balanced across public payers.
CLARITY is a national outlier on several Medicare codes, indicating unusually large volume relative to peers. The provider ranks #7/973 for U0003 (99th percentile, labelled an extreme outlier) and #4/465 for G2023 (99th percentile, extreme outlier), and #7/1090 for U0005 (99th percentile, extreme outlier), demonstrating it is a major national player for high‑throughput SARS‑CoV‑2 molecular testing and specimen collection. These rankings point to capacity or contract arrangements that produce volumes far above typical lab peers.
By contrast, its Medicaid footprint is typical to moderately high within Illinois. For U0003 in Medicaid it ranks #86/350 (76th percentile, described as typical), for 87811 it ranks #35/548 (94th percentile, typical), and for G2023 it ranks #44/396 (89th percentile, typical). These in‑state ranks indicate respectable but not extreme Medicaid market share for the same COVID‑19 testing services it offers nationally through Medicare.
Service mix implies a high‑throughput diagnostic laboratory workflow. High volumes of U0003 and U0005 (molecular NAAT methods) alongside large counts of G2023 (specimen collection) and 87811 (immunoassay) indicate the organization combines both centralized molecular testing and point‑of‑collection specimen processing/collection operations rather than exclusively small‑scale, clinician‑office testing. This mix supports an operational profile centered on mass testing throughput and specimen logistics.
The provider has relatively short tenure in the NPI file, enumerated on 2022-02-23 (~4 years ago), yet has already produced multi‑million dollar Medicare revenue and substantial claim volume. This rapid scale‑up since enumeration is consistent with a lab that expanded during the COVID‑19 pandemic response and captured high testing volume quickly.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 33,640 | $70 | $2.5M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 48,970 | $20 | $1.1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 33,530 | $30 | $838.3K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 18,850 | $40 | $772.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3,220 | $50 | $160.9K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 2,600 | $30 | $72.8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4,820 | $10 | $67.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 3,140 | $20 | $53.4K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 86 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 57 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 44 | 400 | 550 | $20 | $90.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 35 | 550 | 240 | $40 | $42.4K |
Other providers in the same ZIP code as Clarity Testing Services, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Legacy Medical Care Inc | IL | Federally Qualified Health Center (FQHC) | $0 | $42.6M |
| Universal Health Solutions Inc | IL | Clinical Medical Laboratory | $12.4M | $258.4K |
| A-z & Medical Supply Inc | IL | Durable Medical Equipment & Medical Supplies | $0 | $9.3M |
| Village Of Arlington Heights A | IL | Land Ambulance | $1M | $7.4M |
| Clearbrook | IL | Case Management Agency | $0 | $6.1M |
| Senad Osmanovic | IL | Ophthalmology Physician | $1.6M | $1.3M |
| Northwest Community Day Surgery Center Ii LLC | IL | Ambulatory Surgical Clinic/Center | $2.6M | $0 |
| Richard Siegel | IL | Hematology & Oncology Physician | $1.4M | $0 |
| Urszula Sobol | IL | Hematology & Oncology Physician | $1.2M | $12K |
| Randy Rich | IL | Hematology & Oncology Physician | $1.2M | $750 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.